# Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1

> **NCT01717638** · PHASE3 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 805 (actual)

## Conditions studied

- Meningococcal Disease
- Meningococcal Meningitis

## Interventions

- **BIOLOGICAL:** 1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine
- **BIOLOGICAL:** 2 doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine

## Key facts

- **NCT ID:** NCT01717638
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2013-09
- **Final completion:** 2013-10
- **Target enrollment:** 805 (ACTUAL)
- **Last updated:** 2015-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01717638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01717638, "Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01717638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*